Ian Kalvinskas Pediatric Liver Cancer Early Detection and Screening Act
- Sponsor
- Rep. Costa, Jim [D-CA-21]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Sep 18, 2025
Bottom line
The bill aims to improve early detection and treatment outcomes for pediatric liver diseases through research and public awareness, without authorizing new federal spending.
What it actually does
This bill directs the Government Accountability Office (GAO) to conduct a study on pediatric liver disease, including federally funded early detection initiatives, trends in transplant wait-list mortality, and the cost-effectiveness of adding direct-bilirubin screening to newborn panels. It also mandates the Secretary of Health and Human Services to establish a public education program on early signs of pediatric liver disease and the option of living liver donation, explicitly stating that no additional funds are authorized for this program.
Proponents argue
Supporters argue that this bill addresses a critical public health need by promoting early detection of serious pediatric liver conditions, which can significantly improve survival rates and reduce the need for urgent transplants. They highlight the importance of the GAO studies in informing future policy and the public education program in empowering parents and healthcare providers, while also addressing organ scarcity through awareness of living liver donation.
Opponents contend
Critics might argue that while the intent is laudable, the bill's impact is limited by its lack of authorized funding for the public education program, potentially making it ineffective. They might also suggest that directing the GAO to study these issues without immediate actionable mandates could delay tangible improvements, or that existing programs could be leveraged more effectively without new legislation.
The bill is very short and easy to read, making it highly accessible for anyone wishing to understand its provisions quickly.
Section 3
GAO Study on Pediatric Liver Disease Outcomes and Screening Panels
This section mandates the Government Accountability Office (GAO) to conduct a comprehensive study on pediatric liver disease. The study will investigate federally funded initiatives for early detection and treatment of pediatric liver tumors, analyze trends in pediatric liver-transplant wait-list mortality across various demographics, and assess the cost-effectiveness of incorporating direct-bilirubin screening into state newborn screening panels for cholestatic liver diseases like biliary atresia. The GAO must report its findings to Congress within one year of the bill's enactment.
Supporters argue
Supporters argue that this study is crucial for evidence-based policymaking, providing vital data on the effectiveness of current initiatives, identifying disparities in transplant access, and evaluating the economic and health benefits of enhanced newborn screening. This foundational research is necessary to drive meaningful improvements in pediatric liver health.
Critics contend
No specific opposition is typically raised against studies of this nature, as they are generally seen as beneficial for informing policy. However, some might argue that the issues are already well-understood or that the study could delay more immediate interventions.
Tradeoffs
The primary tension is between the need for comprehensive data to make informed decisions and the urgency of implementing interventions. While the study provides valuable insights, it defers direct action until its completion.
Section 4
Public Education Program on Pediatric Liver Disease and Living Donation
This section directs the Secretary of Health and Human Services (HHS), through the Health Resources and Services Administration (HRSA) and in consultation with the Centers for Disease Control and Prevention (CDC), to create and distribute public education materials. These materials will inform the public about the early signs of pediatric liver disease and the safety and option of living liver donation. The program is intended to be coordinated with existing CDC and HHS public health initiatives. A GAO report on the program's results is required after three years, and critically, no additional funds are authorized to be appropriated for this section.